Major Depressive Disorder Clinical Trial
— STANDOfficial title:
Brief, Primary Care Cognitive Behavioral Therapy (CBT) for Unmedicated Youth
Verified date | July 2012 |
Source | Kaiser Permanente |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
STAND is a research study testing a way to help teens between 12-18 years of age who have
symptoms of sadness or depression. The study hopes to learn if teens do better if they get
five to nine counseling sessions of cognitive behavioral therapy coordinated with the
support of their doctor. All teens who join the study will keep seeing their doctor as
usual.
Teens and a parent are interviewed briefly over the phone to see if they are appropriate for
the study. If they qualify for the study, there is an hour-long interview with teen over the
telephone and a 30 minute interview with the parent. The interview will include questions
about the teen's mood, feelings, behavior, and how they get along with friends and family
members. The parent is also asked about his or her own feelings and mood. If the teen and
parent join the study, they will be interviewed six more times in the next two years.
Half the teens in the study will also meet with a research counselor for five to nine
individual, weekly sessions that last about 50 minutes each. Whether a teen attends the
weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned
to these sessions, they will learn ways to deal with stress and feel better. If teens take
part in the counseling sessions, the study counselor will also talk to the teen's doctor
from time to time to help plan for the best possible care.
Status | Completed |
Enrollment | 212 |
Est. completion date | January 2014 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Age 12-18 - Current diagnosis of Major Depressive Disorder Exclusion Criteria: - Psychosis - Bipolar - Taking anti-depressant medication - Significant intellectual impairment - Recent treatment with cognitive behavioral therapy |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Kaiser Permanente Center for Health Research | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Kaiser Permanente | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The two Primary outcomes are (a) recovery of response from the index episode of major depression and (b) improvements in continuous depression symptomatology . | Assessment at 1 3, 6,12, 18 and 24 months, | Yes | |
Secondary | Secondary outcomes include depression response; rates of new, recurrent episodes of MDD during follow-up; improvement in psychosocial function; clinical improvements; and reduction in depression-related dysfunction. | Assessment at 1 3, 6,12, 18 and 24 months, | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |